Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 9/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 7/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30195142 | 0.91 | AGTR2 (0.42) | PIK3CAAGTR2EDNRAABCB11CYP3A4 | |
| SCHEMBL30194978 | 0.91 | AGTR2 (0.47) | PIK3CAAGTR2EDNRAPIK3CDPIK3CB | |
| SCHEMBL30195048 | 0.86 | AGTR2 (0.42) | PIK3CAAGTR2EDNRAABCB11CYP3A4 | |
| SCHEMBL30195170 | 0.85 | AGTR2 (0.48) | AGTR2CYP3A4 | |
| SCHEMBL30195009 | 0.84 | AGTR2 (0.47) | AGTR2CYP3A4 | |
| SCHEMBL30195030 | 0.84 | AGTR2 (0.42) | AGTR2EDNRACYP3A4 | |
| SCHEMBL30195090 | 0.84 | AGTR2 (0.43) | AGTR2CYP3A4 | |
| SCHEMBL30195087 | 0.83 | AGTR2 (0.47) | AGTR2CYP3A4 | |
| SCHEMBL30195053 | 0.83 | AGTR2 (0.49) | AGTR2EDNRACYP3A4 | |
| SCHEMBL30195091 | 0.83 | ALOX5AP (0.47) | AGTR2EDNRACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4367110-A1 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | Vicore Pharma AB (SE) | 2024-05-15 | — | — | EP | claimed |
| CN-117916229-A | Novel selective angiotensin II compounds | 维科尔药物公司 | 2024-04-19 | — | — | CN | claimed |
| WO-2023281271-A1 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | VICORE PHARMA AB (SE) | 2023-01-12 | — | — | WO | claimed |
| US-12441718-B2 | Selective angiotensin II compounds | VICORE PHARMA AB (SE) | 2025-10-14 | — | — | US | disclosed |
| US-20250101010-A1 | SELECTIVE ANGIOTENSIN II COMPOUNDS | VICORE PHARMA AB (SE) | 2025-03-27 | — | — | US | disclosed |
| CN-117916229-A | Novel selective angiotensin II compounds | 维科尔药物公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023281271-A1 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | VICORE PHARMA AB (SE) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101010-A1 | SELECTIVE ANGIOTENSIN II COMPOUNDS | AGTR1, AGTR2, REN | PIK3CA 3997/4885AGTR2 2/4885EDNRA 34/4885 |
| US-12441718-B2 | Selective angiotensin II compounds | AGTR1, AGTR2, REN | PIK3CA 3997/4885AGTR2 2/4885EDNRA 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.